Arylamine N-Acetyltransferases: What We Learn from Genes and Genomes
The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Arylamine N-acetyltransferases (NATs) are phase II xenobiotic metabolizing enzymes, catalyzing acetyl-CoA-dependent N- and O-acetylation reactions. All NATs have a conserved cysteine protease-like Cys-His-Asp catalytic triad inside their active site cleft. Other residues determine substrate specificity, while the C-terminus may control hydrolysis of acetyl-CoA during acetyltransfer. Prokaryotic NAT-like coding sequences are found in >30 bacterial genomes, including representatives of Actinobacteria, Firmicutes and Proteobacteria. Of special interest are the nat genes of TB-causing Mycobacteria, since their protein products inactivate the anti-tubercular drug isoniazid. Targeted inactivation of mycobacterial nat leads to impaired mycolic acid synthesis, cell wall damage and growth retardation. In eukaryotes, genes for NAT are found in the genomes of certain fungi and all examined vertebrates, with the exception of canids. Humans have two NAT isoenzymes, encoded by highly polymorphic genes on chromosome 8p22. Syntenic regions in rodent genomes harbour two Nat loci, which are functionally equivalent to the human NAT genes, as well as an adjacent third locus with no known function. Vertebrate genes for NAT invariably have a complex structure, with one or more non-coding exons located upstream of a single, intronless coding region. Ubiquitously expressed transcripts of human NAT1 and its orthologue, murine Nat2, are initiated from promoters with conserved Sp1 elements. However, in humans, additional tissue-specific NAT transcripts may be expressed from alternative promoters and subjected to differential splicing. Laboratory animals have been widely used as models to study the effects of NAT polymorphism. Recently generated knockout mice have normal phenotypes, suggesting no crucial endogenous role for NAT. However, these strains will be useful for understanding the involvement of NAT in carcinogenesis, an area extensively investigated by epidemiologists, often with ambiguous results.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Initial sequencing and comparative analysis of the mouse genome
Mouse Genome Sequencing Consortium (2002) · Nature · doi:10.1038/nature01262 · Cited by 7,187 · cited 3×
“Following completion of the mouse genome project (Mouse Genome Sequencing Consortium, 2002), it has become possible to determine the exact organisation of the Nat gene cluster in mice (Fig.”
Hein, D. W. (2002) · Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis · doi:10.1016/s0027-5107(02)00153-7 · Cited by 518 · cited 2×
“…(Bunschoten et al., 2000; Labuda et al., 1999), heteroduplex analysis (Hubbard et al., 1998; Lin et al., 1998), capillary-based real-time PCR with melting curve analysis on Roche’s Light-Cycler (Wikman et al., 2001) or the TaqMan genotyping assay by Applied Biosystems (Doll and Hein, 2001, 2002).”
BackgroundMethodMicrobial Genes in the Human Genome: Lateral Transfer or Gene Loss?
Salzberg, S. L., White, O., Peterson, J., & Eisen, J. A. (2001) · Science · doi:10.1126/science.1061036 · Cited by 326 · cited 1×
“Recent studies also suggest that bacterial infections may have served in the evolutionary past as a route for lateral transfer of prokaryotic genes to the vertebrate genomes (Salzberg et al., 2001).”
BackgroundBell, D. A., Taylor, J. A., Butler, M. A., Stephens, E. A., Wiest, J., Brubaker, L. H., Kadlubar, F. F., & Lucier, G. W. (1993) · Carcinogenesis · doi:10.1093/carcin/14.8.1689 · Cited by 292
Functional characterization of human N-acetyltransferase 2 (NAT2) single nucleotide polymorphisms
Fretland, A. J., Leff, M. A., Doll, M. A., & Hein, D. W. (2001) · Pharmacogenetics · doi:10.1097/00008571-200104000-00004 · Cited by 141
Deloménie, C., Fouix, S., Longuemaux, S., Brahimi, N., Bizet, C., Picard, B., Denamur, E., & Dupret, J.-M. (2001) · Journal of Bacteriology · doi:10.1128/jb.183.11.3417-3427.2001 · Cited by 117
Cited by
Fluorogenic probes for disease-relevant enzymes
Zhang, J., Chai, X., He, X.-P., Kim, H.-J., Yoon, J., & Tian, H. (2019) · Chemical Society Reviews · doi:10.1039/c7cs00907k · Cited by 606
Goldstone, J. V., Hamdoun, A., Cole, B. J., Howard-Ashby, M., Nebert, D. W., Scally, M., Dean, M., Epel, D., Hahn, M. E., & Stegeman, J. J. (2006) · Developmental Biology · doi:10.1016/j.ydbio.2006.08.066 · Cited by 280
“Multiple NAT homologs are present in bacterial and vertebrate genomes, including two arylamine NATs in humans mapped to the same chromosome locus (Boukouvala and Fakis, 2005), one of which has roles in neuronal development (Sugiura et al., 2003).”
BackgroundPharmGKB summary: very important pharmacogene information for N-acetyltransferase 2
McDonagh, E. M., Boukouvala, S., Aklillu, E., Hein, D. W., Altman, R. B., & Klein, T. E. (2014) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0000000000000062 · Cited by 146
Self-citationGenetic Polymorphism in N-Acetyltransferase (NAT): Population Distribution of NAT1 and NAT2 Activity
Walker, K., Ginsberg, G., Hattis, D., Johns, D. O., Guyton, K. Z., & Sonawane, B. (2009) · Journal of Toxicology and Environmental Health, Part B · doi:10.1080/10937400903158383 · Cited by 140
Hein, D. W., & Doll, M. A. (2012) · Pharmacogenomics · doi:10.2217/pgs.11.122 · Cited by 121
Metadata
- Authors
- Boukouvala, S., & Fakis, G.
- Venue
- Drug Metabolism Reviews
- Publisher
- Informa UK Limited
- Published
- 2005-01
- Volume
- 37
- Issue
- 3
- Pages
- 511-564
- ISSN
- 0360-2532 (ISSN-L)
- 1097-9883
- OpenAlex
- W2149298729
- Cited by
- 137
- References
- 6
- FWCI
- 10.24
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Arylamine N-Acetyltransferases: What We Learn from Genes and Genomes. https://app.cochat.ai/papers/10.1080/03602530500251204
- The paper
- Boukouvala, S., & Fakis, G. (2005). Arylamine N-Acetyltransferases: What We Learn from Genes and Genomes. Drug Metabolism Reviews. https://doi.org/10.1080/03602530500251204
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.